Table 3 Best response to treatment and durability of response (response-evaluable population)
Bortezomib-rituximab (N=96) | Rituximab (N=95) | Odds ratio (95% CI) | P-value | |
|---|---|---|---|---|
ORR, n (%) | 57 (59) | 35 (37) | 0.399 (0.223, 0.715) | 0.002 |
CR/CRu*, n (%) | 12 (13) | 6 (6) | 0.472 (0.169, 1.314) | 0.145 |
PR, n (%) | 45 (47) | 29 (31) | – | – |
Stable disease, n (%) | 24 (25) | 32 (34) | – | – |
Progressive disease, n (%) | 15 (16) | 28 (29) | – | – |
Durable (≥6 months) response, n (%) | 43 (45) | 25 (26) | 0.440 (0.240, 0.809) | 0.008 |
Median DOR, months | 10.4 | 12.1 | – | – |
Median DOR (CR/CRu*), months | 16.5 | 10.5 | – | – |